A comparison of health-related quality of life in chronic intestinal failure and end-stage kidney disease: A cross-sectional study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background
There is inequal access to treatment and scarce evidence on how the disease burden in chronic intestinal failure (CIF) compares to other chronic nonmalignant types of organ failure. Therefore, we compared the health-related quality of life (HRQOL) of people with CIF with that of people with end-stage kidney disease (ESKD) receiving hemodialysis (HD). These groups were selected for comparison as they have similar treatment characteristics. We hypothesized that people treated with HD and people with CIF had similarly poor HRQOL.

Methods
HRQOL was evaluated and compared in a cross-sectional study of adult people with CIF and people with ESKD HD at a tertiary hospital in Denmark, using the Short-Form 36 (SF-36).

Results
One hundred forty-one people with CIF and 131 people with ESKD receiving HD were included in the analysis. Both groups reported low scores (<50) for HRQOL on general health, vitality, and role limitation—physical. People with ESKD receiving HD had significantly lower scores than people with CIF regarding physical functioning, general health, and vitality when adjusted for sex and age. No significant difference was found for any other SF-36 domain.

Conclusion
HRQOL was similarly and significantly reduced in people with CIF and in people with ESKD receiving HD. People with ESKD receiving HD had significantly poorer HRQOL than people with CIF in some aspects of physical and mental health. Access to home parenteral support treatment varies among countries that typically provide HD, suggesting an inequality in healthcare based on the type of organ failure.
OriginalsprogEngelsk
TidsskriftJournal of Parenteral and Enteral Nutrition
Vol/bind48
Udgave nummer2
Sider (fra-til)184-191
Antal sider8
ISSN0148-6071
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
G.P.K. has received unrestricted study grants from the Novo Nordisk Foundation, the Danish Cancer Society and European Commission. P.B.J. has received consultancy fees from Albumedix A/S; Protara Therapeutics; Baxter; Coloplast; Ferring Pharmaceuticals; Fresenius Kabi; GLyPharma Therapeutic; Naia Pharmaceuticals; Novo Nordisk Foundation; Shire, a Takeda company; Therachon; VectivBio AG; and Zealand Pharma. J.E. has received consultancy fees from VectivBio AG. When this study and manuscript as created, J.E. worked at Copenhagen University Hospital. At the time of this manuscript being published, J.E. is an employee of Ferring Pharmaceuticals and has been a previous employee of Novo Nordisk A/S.

Publisher Copyright:
© 2023 American Society for Parenteral and Enteral Nutrition.

ID: 382979321